Karuna’s CNS double play

With $42 million in series A funding, Karuna Pharmaceuticals Inc. hopes its combination of muscarinic receptor-targeting therapies can lead to clinical benefits in CNS disorders without the peripheral side effects seen in previous studies.

Along with founding investor PureTech Health PLC (LSE:PRTC), the round included Arch Venture Partners, the Wellcome Trust and Karuna Chairman Steven Paul, as well as undisclosed other backers...